PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical ...
FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.Remaining item relates to manufacturer certificatio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results